Home » Topics » BioWorld Science

BioWorld Science
RSS

Acorda submits MAA to EMA for Inbrija

March 27, 2018

EMA grants PRIME designation for lumasiran in primary hyperoxaluria type 1

March 27, 2018

Amag submits NDA for bremelanotide for hypoactive sexual desire disorder

March 27, 2018

Loxo completes rolling NDA for larotrectinib in U.S.

March 27, 2018

FDA grants breakthrough therapy designation to enfortumab vedotin

March 27, 2018

Protagonist stops phase IIb study of PTG-100 for ulcerative colitis based on futility analysis

March 27, 2018

Allecra reports phase II data on cefepime/AAI-101 in cUTI

March 27, 2018

Phase III trials of rimegepant in migraine meet coprimary endpoints

March 27, 2018

Male contraceptive 11beta-MNTDC reduces testosterone in healthy male volunteers

March 27, 2018

Phase III efficacy and safety data reported for vibegron in overactive bladder

March 27, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...